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Left ventricular electromechanical mapping (LVEMM, also
termed NOGA or Biosense procedure) is derived from a
diagnostic and navigational guidance tool that utilizes ul-
tralow magnetic-field sources and location sensor-tipped
catheter electrodes that trace the catheter-tip position in
three-dimensional (3D) space (1–3). The system recon-
structs electromechanical maps of the left ventricle with
minimal utilization of X-ray fluoroscopy. Primarily,
LVEMM was designed for electrophysiology application
for electrical activation and voltage mapping (CARTO
system, Cordis-Webster, Diamond Bar, California) and
ablation of arrhythmogenic foci (4–6). More recently, this
system was investigated for catheter-based diagnosis of
myocardial function, viability, and ischemia in the cardiac
catheterization setting (7). It has been theorized that maps
generated by the LVEMM system could be utilized for
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localization and identification of viable myocardial regions
based on integration of endocardial electrical potentials and
mechanical signals (8). Also, this platform technology has
been used to investigate the safety, feasibility, and efficacy of
strategies designed for intramyocardial therapeutics using
either integrated laser energy or intramyocardial injection
catheters for angiogenic gene and cell transplantation inves-
tigational strategies for alternative myocardial revasculariza-
tion (9–11).
Because the system collects endocardial electrical signals
(unipolar and bipolar voltages), those signals may reflect the
status of myocardial viability (presence of normal or reduced
voltage), and mechanical maps (end-systolic and end-
diastolic volumes, ejection fraction, and local endocardial
shortening) can provide global and regional contractility
data for the left ventricle, compared simultaneously with
those derived from electrical signals (12–14). Analysis of
mapping details is based on color-coded unipolar and
bipolar endocardial potentials recorded from sensor-tipped
electrodes, and mechanical function represented as local
endocardial shortening maps. Using the LVEMM system in
various in vivo models, the average maximal and mean errors
for repeated same location measurements was found to be as
accurate as 1.26  0.08 mm and 0.54  0.05 mm, and the
overall mean error for location distances measured was 0.73
 0.03 mm (2). Location accuracy assessment in patients
was found to be 0.95  0.80 (median 0.86) mm (3).
The LVEMM system was used in several animal models
to identify electrical and mechanical changes during acute
and chronic myocardial ischemia and myocardial infarction
(12–17). Significant reduction (by 50 to 70% from base-
line values) was found in measured peak-to-peak unipolar
and bipolar voltage amplitudes and local endocardial short-
ening signals in infarcted regions after coronary occlusion
compared with baseline or noninfarcted areas (8,13–15).
Using models that simulated chronic myocardial ischemia
(rather than infarction), electrical signals were found to be
mildly attenuated (by 10% to 25%) in ischemic regions,
while mechanical signals were significantly impaired com-
pared with nonischemic regions (16). It was, thus, presumed
that the mapping technique can provide a unique insight
into myocardial ischemia from “dissociated” electromechan-
ical measurements (mechanical impairment in stunned or
hibernating myocardium and relative preservation of elec-
trical activity vs. a decline in both parameters in infarcted
segments). Moreover, in a canine model of myocardial
infarction, it has been suggested that the catheter-based
LVEMM technique could delineate between infarcts vary-
ing in transmurality by using electrical information derived
from endocardial voltage potentials (17).
In a pilot clinical study, unipolar voltage and local
endocardial shortening were measured in 18 patients with
symptomatic chronic angina and preserved left ventricular
function, who had reversible or fixed myocardial perfusion
defects using single-photon emission computed tomogra-
phy (SPECT) dual isotope imaging study (18). The results
showed significant differences in voltage potentials and local
shortening values between the examined myocardial seg-
ments. The average voltage potentials (14.0  2.0 mV) and
endocardial shortening values (12.5  2.8%) were highest
when measured in myocardial segments with normal perfu-
sion and the lowest (7.5  3.4 mV and 3.4  3.4%) when
measured in myocardial segments with fixed perfusion
defects. Myocardial segments with reversible perfusion de-
fects had intermediate voltage amplitudes and shortening
values (8). Those findings were recently confirmed by
another group of investigators (19), suggestive that, in
patients with myocardial ischemia, electromechanical map-
ping enables a catheter-based assessment of myocardial
viability in the cardiac catheterization laboratory.
In this issue of the Journal, Keck et al. (20) report a series
of 51 patients undergoing LVEMM and correlates the
maps to results of SPECT and positron emission tomogra-
phy (PET) nuclear imaging and transthoracic echocardiog-
raphy. The correlations found in this study between
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LVEMM parameters, echocardiography, nuclear perfusion,
and metabolic imaging were reasonably good. The strongest
correlation that had sufficient sensitivity and specificity to
have potential clinical implications was found between
99mTc tetrofosmin uptake and unipolar voltage, both ob-
tained at rest and, in particular, when excluding the basal
myocardial segments from analysis. Both electrical and
mechanical parameters were highest in normally perfused
segments (11.2  5.0 mV and 8.2  5%) and in segments
with reversible ischemia (11.7  4.7 mV and 7.6  7.3%),
as compared with segments with fixed perfusion defects (6.3
 3.0 mV and 3.5  4.0%, p  0.001 vs. normal and
ischemic segments). Similar observations were made when
calculating the QRS “fragmentation index.” However, even
for this correlation, it should be acknowledged that, to have
a sensitivity of 90% to detect scar tissue, one must find
unipolar voltage as low as 6 mV, and, to have 90% specificity
to exclude the presence of scar tissue, unipolar voltage as
high as 10 mV should be found. As the authors correctly
pointed out in their paper, it means that a relatively large
intermediate zone exists of ill-defined values and myocardial
viability status. In this “gray zone,” the mapping system may
not be able to distinguish accurately between ischemic, scar,
and normal tissue. This conclusion is also valid for the
fragmentation index and, even more so, for the local
endocardial-shortening algorithm, which also shows the
greatest degree of scattered values.
Perhaps the most interesting finding of this study is
derived from the comparison between LVEMM and PET
fluorine-18 fluorodeoxyglucose (FDG) metabolic imaging
in myocardial segments identified as “scar” using SPECT
imaging. “Fixed” segments with preserved FDG uptake that
identified preserved glucose metabolism had a significantly
higher unipolar voltage and lower fragmentation index than
scar tissue that had no FDG uptake using PET metabolic
imaging (7.2  2.7 mV vs. 6.5  2.6 mV vs. 5.0  3.1 mV
for normal vs. limited vs. no FDG uptake, respectively, p 
0.029). The latter finding implies that in some cases
LVEMM may define areas with preserved myocardial
functionality in regions wherein SPECT nuclear perfusion
shows no signs of myocardial viability. However, even for
those signals, a wide variability of measured electrical and
mechanical values exists that makes individual interpreta-
tion somewhat difficult for purposes of individual working
algorithms.
Interestingly, in the current study the authors could not
demonstrate changes in average unipolar voltage amplitudes
within regions defined as ischemic per SPECT compared
with normal perfusion areas. Whether ischemic changes can
be detected by peak-to-peak unipolar voltage potential
measurements is still a matter of controversy. However,
based on our recent clinical report (21), it is probable that
only regions with the most severe degree of myocardial
ischemia (i.e., lowest perfusion grades), that extends
throughout the resting phase, may cause electrical abnor-
malities that can be depicted by reduced voltage amplitudes
recording at rest. In a recent study from our laboratory (21),
we demonstrated a gradual and proportional reduction in
voltage and shortening values in relation to 201Tl uptake
score at rest and redistribution studies in 61 ischemic
patients with relatively preserved left ventricular function.
According to those findings, unipolar voltage 7.4 mV and
local shortening 5.0% had a sensitivity of 78% and 65%,
respectively, with a specificity of 68% and 67% to detect
viable myocardial segments. Also, unipolar voltage values of
12.3 mV and 5.4 mV had 90% specificity and sensitivity,
respectively, to predict viable tissue, data similar, although
not identical, to those of Keck et al. (20).
In another study (22) the use of LVEMM was evaluated
to distinguish between nonviable and viable myocardium in
31 patients with ischemic cardiomyopathy having a mean
ejection fraction of 30%. Unipolar voltage amplitudes and
local shortening was compared with dysfunctional regions,
identified by 3D echocardiography and characterized as
nonviable using PET imaging. The optimum nominal
discriminatory unipolar voltage amplitude between nonvia-
ble and viable dysfunctional myocardium was 6.5 mV in that
study. As in other works, a great overlap was observed
between groups of viable and nonviable myocardial seg-
ments. Between-patient variability was the main component
responsible for the large variability of measured data. How-
ever, when normalized amplitudes were used in this partic-
ular study (e.g., highest amplitude expressed as 100%), an
improved discriminatory value was found, with a 78%
sensitivity and specificity for the normalized value compared
with 68% of the nominal value in distinguishing between a
viable and nonviable myocardium. It was, thus, appropri-
ately concluded that, although endocardial electrical ampli-
tude mapping allows distinction between viable and nonvi-
able areas in ischemic cardiomyopathy patients, this
technique displays a wide scatter and that a better distinc-
tion could be obtained using individual normalization of
voltage amplitude values.
A major question that arises from the above cited works
is: “What is the potential merit of LVEMM as an invasive
diagnostic method designed for assessing myocardial viabil-
ity or ischemia in the cardiac catheterization laboratory?” It
has been proposed by the authors (20) as well as others (7),
that, in patients without recent assessment of myocardial
viability who undergo coronary revascularization, informa-
tion concerning regional viability might be useful for clinical
decision-making before revascularization procedures. Also,
this mapping technique may assist efficient delivery of
catheter-based therapy in patients with left ventricular
dysfunction who undergoing catheterization by providing
online assessment of viability. However, the study by Keck
et al. (20) also highlights that more data is still needed for
enabling improved differentiation between viable and non-
viable regions and between ischemic and normally perfused
myocardium. As observed in most previous studies that
involved validation of LVEMM, this study found consid-
erable overlap in the electromechanical mapping values
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between groups. The overlap is probably caused by differ-
ences in methods of LV segmentation used for the 3D
LVEMM compared with the nuclear, metabolic, and echo-
cardiographic imaging techniques where regions of normal,
ischemic, viable, and scarred myocardium do not fall exactly
within segmental borders. As a result, each segment may
traverse the boundaries between regions of differing viability
and contractility. Scattering may also results from a true
variability between individual patients in endocardial volt-
age amplitudes “output” and the impact of left ventricular
thickness and dimension upon measured values and algo-
rithms used to assessing global and regional mechanical
activity. A greater overlap between scattered nominal data is
still a limitation of the mapping technique that could be
improved by normalizing measured electrical and mechan-
ical values by using improved electromechanical algorithms.
It should be notable that the threshold values to define
myocardial viability are not uniform among the studies.
Voltage amplitudes within a range of 7 mV to 9 mV might
represent viable tissue in one patient as in another case this
may represent a nonviable tissue, especially when high (e.g.,
15 mV) normal “reference” electrical values coexist. An-
other limitation of using the LVEMM technique is the lack
of viability assessment in relation to changes in regional
mechanical or electrical functions after coronary revascular-
ization procedures. A recent study showed that voltage
mapping enabled the prediction of functional recovery in
regional and global left ventricular function among 46
patients with prior myocardial infarction who underwent
coronary revascularization and compared with FDG PET
and Tc-99m sestamibi SPECT (23). Regional unipolar
electrogram amplitude was 11.0  3.6 mV in regions with
normal perfusion, 9.0  2.8 mV in regions with reduced
perfusion and preserved FDG-uptake, and 6.5  2.6 mV in
scar regions (p  0.001). At a threshold amplitude of 7.5
mV, the sensitivity and specificity for detecting viable (by
PET/SPECT) myocardium were 77% and 75%, respec-
tively. Functional recovery was further assessed in 25 pa-
tients with a follow-up angiography using the centerline
method. In infarct areas with electrogram amplitudes 7.5
mV, improvement of regional wall motion from2.4 1.0
per chord to1.5 1.1 per chord (p 0.01) was observed,
whereas, in infarct areas with amplitudes 7.5 mV, wall
motion remained unchanged at follow-up. More data are
needed, however, to validate those promising findings. In
addition, the appropriate thresholds for defining myocardial
viability and ischemia should be determined more defini-
tively before a widespread use of this technique could be
recommended for routine diagnostic purposes. Finally,
mapping techniques should become: 1) faster; 2) simplified;
and 3) uniformly taught and practiced to enable more
generalized use of the technique and adequate comparison
between operators and centers.
Before such data from endocrinal mapping will be useful
in decision-making about whether to perform revasculariza-
tion procedures, considerably more work is required and
especially in patients with impaired myocardial function
who are candidates for conventional (e.g., angioplasty or
bypass surgery) or “alternative” (e.g., direct myocardial
revascularization or angiogenesis-promoting interventions)
myocardial revascularization procedures. It remains to be
established whether such precise localized diagnosis directed
towards viable myocardial zones and coupled with myocar-
dial revascularization would enhance the therapeutic benefit
obtained by myocardial revascularization procedures
whether or not preceded by noninvasive studies. The answer
to those questions would dictate whether left ventricular
mapping is, indeed, ready for “prime time” as a diagnostic
cardiac procedure.
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